Table 3.
Peptide Sequencea | Peptide Nameb | Gene | FC(log2)c |
---|---|---|---|
Q(−17.03)EDAELQP | CARTPT | 3.50 | |
Q(−17.03)EDAELQPR | CARTPT | 2.50 | |
FLGEAYHHVPESQ | CHGB | 2.19 | |
FLGEAYHHVPESQRD | CHGB | 2.20 | |
LGVLFNPYYDPLQWKSSRFE | CHGB | 1.15 | |
Q(−17.03)YDRVAELDQLLHY | BAM-1745 | CHGB | 0.92 |
SSPETLISDLLMRESTENVPRTRLEDPSMW | C-terminal flanking peptide | NPY | 2.52 |
YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY(−.98) | Neuropeptide Y | NPY | 3.46 |
AADQDLGPEAPPEGVLGA | PEN-18 | PCSK1N | 1.91 |
AADQDLGPEAPPEGVLGAL | PEN-19 | PCSK1N | 1.96 |
AADQDLGPEAPPEGVLGALL | PEN-20 | PCSK1N | 1.36 |
AADQDLGPEAPPEGVLGALLRV | PEN | PCSK1N | 1.59 |
LENPQPQAPA | LittleLEN | PCSK1N | 2.61 |
LENPQPQAPARRLLPP | BigLEN | PCSK1N | 2.16 |
SLSAASPPMTEAGTPRRF | LittleSAAS | PCSK1N | 1.78 |
SVPRGEAAGAVQELARALAHLLEAERQE | BigGAV | PCSK1N | 1.57 |
VKMALQQEGFD | PCSK2 | 1.14 | |
YGGFLRKYP | β-neoendorphin | PDYN | 2.33 |
YGGFLRKYPK | α-neoendorphin | PDYN | 1.70 |
MDELYPVEPEEEANGGEVL | PENK | 1.70 | |
MDELYPVEPEEEANGGEVLA | PENK | 1.48 | |
SPQLEDEAKEL | PENK | 1.77 | |
SPQLEDEAKELQ | PENK | 2.05 | |
VGRPEWWMDYQ | PENK | 1.45 | |
YGGFMRF | Met-enkephalin-Arg-Phe | PENK | 2.09 |
YGGFMRGL | Met-enkephalin-Arg-Gly-Leu | PENK | 2.14 |
EIGDEENSAKFPI(−.98) | Neuropeptide-glutamic acid-isoleucine | PMCH | 1.44 |
ALNSVAYERNAMQNYE | C-terminal flanking peptide | TAC1 | 2.21 |
RPKPQQFFGLM(−.98) | Substance P | TAC1 | 1.54 |
ASWTREPLE | TRH | 2.51 | |
ASWTREPLEE | TRH | 2.36 | |
EDEAAWSLDRTQQ | TRH | 2.74 |
Post-translational modifications are indicated by mass change observed by mass spectrometry. Amidation = (−.98), pyroglutamylation = (−17.03).
Peptide common names inferred from analogy to well-annotated rat sequence.
Fold-change values are given for Oct./Aug. comparison. A positive value indicates the peptide is higher abundance in Oct.